Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Medicina Cutanea Ibero-Latino-Americana
|
January 1, 1974
[Chronic light dermatitis, its relation with actinic reticuloid, the photosensitizing eczema and the persistent reactions to light]
J Pinol Aguadé, M Lecha, T Estrach, et al.
Medicina Clinica
|
February 24, 1990
[Primary malignant melanoma of the skin. Retrospective study of 375 cases. Clinical aspects and histology]
T Castel, M Baradad, J Castro, et al.
American Journal of Human Genetics
|
August 1, 1995
Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene
S Puig, A Ruiz, C Lázaro, et al.
Anticancer Research
|
July 22, 2005
S-100beta and MIA in advanced melanoma in relation to prognostic factors
J M Auge, R Molina, X Filella, et al.
Melanoma Research
|
July 13, 2000
Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Hospital Clinic Malignant Melanoma Group, University of Barcelona
S Puig, J Castro, P J Ventura, et al.
Dermatologica
|
January 1, 1991
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy
T Castel, J Estapé, N Viñolas, et al.
Journal of Medical Genetics
|
June 30, 2000
CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia
A Ruiz, S Puig, J Malvehy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis
B Mellado, D Colomer, T Castel, et al.
Anticancer Research
|
March 14, 2007
Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma
M González Cao, J M Auge, R Molina, et al.
Cancer Immunology, Immunotherapy : CII
|
March 5, 2004
Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate
R Vilella, D Benítez, J Milà, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Medicina Cutanea Ibero-Latino-Americana
|
January 1, 1974
[Chronic light dermatitis, its relation with actinic reticuloid, the photosensitizing eczema and the persistent reactions to light]
J Pinol Aguadé, M Lecha, T Estrach, et al.
Medicina Clinica
|
February 24, 1990
[Primary malignant melanoma of the skin. Retrospective study of 375 cases. Clinical aspects and histology]
T Castel, M Baradad, J Castro, et al.
American Journal of Human Genetics
|
August 1, 1995
Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene
S Puig, A Ruiz, C Lázaro, et al.
Anticancer Research
|
July 22, 2005
S-100beta and MIA in advanced melanoma in relation to prognostic factors
J M Auge, R Molina, X Filella, et al.
Melanoma Research
|
July 13, 2000
Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Hospital Clinic Malignant Melanoma Group, University of Barcelona
S Puig, J Castro, P J Ventura, et al.
Dermatologica
|
January 1, 1991
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy
T Castel, J Estapé, N Viñolas, et al.
Journal of Medical Genetics
|
June 30, 2000
CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia
A Ruiz, S Puig, J Malvehy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis
B Mellado, D Colomer, T Castel, et al.
Anticancer Research
|
March 14, 2007
Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma
M González Cao, J M Auge, R Molina, et al.
Cancer Immunology, Immunotherapy : CII
|
March 5, 2004
Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate
R Vilella, D Benítez, J Milà, et al.
Page
of 7